Orbis
Orbis International Equity
International Mid-cap
Dec 2024 → Dec 2025
Our archive holds 5 letters from this strategy, behind 5 investment theses and positions in 5 companies. Every quote below is copied verbatim from the letter it came from.
5 letters in 2 years — follow all of Orbis for every strategy.
Its investment theses
- Genmab A/SDec 2025Genmab A/S is a Danish biotech with a robust pipeline and founder-led R&D, trading below the value of existing cash flows and offering significant upside optionality.
- ICON plcDec 2025ICON plc is a leading CRO trading at a depressed multiple due to temporary headwinds but supported by strong secular demand for healthcare innovation.
- IMAX CorporationDec 2025IMAX Corporation is a global premium theatrical technology platform with scarce, high-demand assets and a powerful brand benefiting from the value of the theatrical window and local content growth.
- Jardine MathesonSep 2025Jardine Matheson is a storied Asian conglomerate focused on capital allocation across leading businesses in consumer services, real estate, and automotive sectors, currently undervalued with strong long-term growth potential.
- FirstServiceDec 2024FirstService is a resilient and underappreciated company with strong growth potential in property management and essential services, boasting predictable revenue and a shareholder-focused culture.